Skip to content
value.today

Genetix Pharmaceuticals Inc

Total raised
$187 M
4 rounds on record
Latest round
$75 M
Sep 2021
First round on record
Mar 2010
Today
Private
See the company page

Genetix Pharmaceuticals Inc is listed today as Bluebird Bio, Inc.: market value, financials and filings are on its company page.

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Genetix Pharmaceuticals Inc
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2021$75 MNo. 4$50 to $250 million

Genetix Pharmaceuticals Inc: Raise no. 4, Sep 2021

Investors in this round

2 investors had bought by the notice of Sep 21, 2021: 2 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Genetix Pharmaceuticals Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$75 M of $75 M offered
Smallest investment taken
no minimum stated
What was sold
equity, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Chip Baird · Executive Officer
  • Jason Cole · Executive Officer
  • Nick S. Leschly · Executive Officer, Director
  • Daniel S. Lynch · Director
  • Denice R. Torres · Director
  • John S. Agwunobi · Director
  • Mark R. Vachon · Director
  • Ramy S. Ibrahim · Director
  • Wendy S. Dixon · Director
  • William R. Sellers · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Chip Baird, Chief Financial Officer. Source: SEC Form D, newest notice filed Sep 21, 2021. Read the notice at the SEC.

equitySEC
Jul 2012$60 MNo. 3$50 to $250 million

Genetix Pharmaceuticals Inc: Raise no. 3, Jul 2012

Investors in this round

17 investors had bought by the notice of Jul 25, 2012: 17 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Genetix Pharmaceuticals Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$60 M of $60 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Jeffrey T. Walsh · Executive Officer
  • Nick Leschly · Executive Officer, Director
  • Axel Polack · Director
  • Daniel S. Lynch · Director
  • Geert-Jan Mulder · Director
  • John M. Maraganore · Director
  • Robert Tepper · Director
  • Steven Gillis · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Nick Leschly, President. Source: SEC Form D, newest notice filed Jul 25, 2012. Read the notice at the SEC.

equitySEC
Apr 2011$15 MNo. 2$10 to $50 million

Genetix Pharmaceuticals Inc: Raise no. 2, Apr 2011

Investors in this round

5 investors had bought by the notice of Apr 27, 2011: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Genetix Pharmaceuticals Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$15 M of $30 M offered; $15 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Nick Leschly · Executive Officer, Director
  • Axel Polack · Director
  • Geert-Jan Mulder · Director
  • Robert Tepper · Director
  • Steven Gillis · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Nick Leschly, President. Source: SEC Form D, newest notice filed Apr 27, 2011. Read the notice at the SEC.

equitySEC
Mar 2010$38 MNo. 1$10 to $50 million

Genetix Pharmaceuticals Inc: Raise no. 1, Mar 2010

Investors in this round

5 investors had bought by the notice of Apr 27, 2011: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 8 investors are named for Genetix Pharmaceuticals Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$38 M of $38 M offered
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Nick Leschly · Executive Officer, Director
  • Axel Polack · Director
  • Geert-Jan Mulder · Director
  • Robert Tepper · Director
  • Steven Gillis · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Nick Leschly, President. Source: SEC Form D and 1 amendment, newest notice filed Apr 27, 2011. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Genetix Pharmaceuticals Inc chose not to state its revenue in its newest notice of a funding round (Sep 2021).

    SEC Form D · Sep 2021

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Sep 2021

That is all the official record says: Genetix Pharmaceuticals Inc has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services of Genetix Pharmaceuticals Inc are on record.

Investors#

8 named in official filings. Open an investor to see everything it has backed.

Investors in Genetix Pharmaceuticals Inc
InvestorKindAmountRoundRoleSource
Arch Venture Fund VII LPVenture capitalnot statednot statedHeld Series C and D preferred stock, 10% owner (Form 3, 2013)SEC Form 3
ARCH Venture Partners VII, LLCVenture capitalnot statednot statedHeld Series C and D preferred stock, 10% owner (Form 3, 2013)SEC Form 3
ARCH Venture Partners VII, L.P.Venture capitalnot statednot statedHeld Series C and D preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Third Rock Ventures GP, L.P.Venture capitalnot statednot statedHeld Series B, C and D preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Third Rock Ventures LPVenture capitalnot statednot statedHeld Series B, C and D preferred stock, 10% owner (Form 3, 2013)SEC Form 3
TRV GP, LLCOthernot statednot statedHeld Series B, C and D preferred stock, 10% owner (Form 3, 2013)SEC Form 3
TVM Capital GmbHFund or asset managernot statednot statedHeld Series A-1, A-2, B, C and D preferred stock, 10% owner (Form 3, 2013)SEC Form 3
TVM V Life Science Ventures Gmbh & Co KGVenture capitalnot statednot statedHeld Series A-1, A-2, B, C and D preferred stock, 10% owner (Form 3, 2013)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 17 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Genetix Pharmaceuticals Inc
NameRoleNamed in
Chip BairdExecutive officerSep 2021
Jason ColeExecutive officerSep 2021
Nick S. LeschlyExecutive officerSep 2021
Jeffrey T. WalshExecutive officerJul 2012
Nick LeschlyExecutive officerJul 2012
Daniel S. LynchDirectorSep 2021
Denice R. TorresDirectorSep 2021
John S. AgwunobiDirectorSep 2021
Mark R. VachonDirectorSep 2021
Nick S. LeschlyDirectorSep 2021
Ramy S. IbrahimDirectorSep 2021
Wendy S. DixonDirectorSep 2021
William R. SellersDirectorSep 2021
Axel PolackDirectorJul 2012
Geert-Jan MulderDirectorJul 2012
John M. MaraganoreDirectorJul 2012
Nick LeschlyDirectorJul 2012
Robert TepperDirectorJul 2012
Steven GillisDirectorJul 2012
Geert-Jan A. MulderDirectorMar 2010
James A. GeraghtyDirectorMar 2010

About

Company in Cambridge, United States.